Analyst Ratings for [CRBP] Corbus Pharmaceuticals Holdings, Inc.

2/28/25	Initiated	Outperform	X
CRBP Corbus Pharma William Blair
12/2/24	Initiated	Overweight	X
CRBP Corbus Pharma Piper Sandler
7/30/24	Initiated	Outperform	X
CRBP Corbus Pharma Wedbush
$85
7/22/24	Resumed	Buy	X
CRBP Corbus Pharma H.C. Wainwright
$80
6/26/24	Initiated	Buy	X
CRBP Corbus Pharma B. Riley Securities
$85
6/3/24	Reiterated	Outperform	X
CRBP Corbus Pharma Oppenheimer
$60 $80
5/13/24	Initiated	Outperform	X
CRBP Corbus Pharma RBC Capital Mkts
$77
3/6/24	Upgrades	Hold Buy	X
CRBP Corbus Pharma Jefferies
$4 $46
4/5/19	Initiated	Buy	X
CRBP Corbus Pharma Jefferies
3/20/19	Initiated	Outperform	X
CRBP Corbus Pharma Oppenheimer
$28
1/11/19	Reiterated	Overweight	X
CRBP Corbus Pharma Cantor Fitzgerald
$36 $38
12/26/18	Initiated	Buy	X
CRBP Corbus Pharma H.C. Wainwright
$24
12/7/18	Initiated	Outperform	X
CRBP Corbus Pharma RBC Capital Mkts
$23
10/24/18	Initiated	Buy	X
CRBP Corbus Pharma B. Riley FBR
$22

CRBP Corbus Pharmaceuticals Holdings, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's product, anabasum is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Anabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing anabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).